Cargando…
Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy
OBJECTIVE: To determine the prevalence and features of fatty liver disease in spinal and bulbar muscular atrophy (SBMA). METHODS: Two groups of participants with SBMA were evaluated. In the first group, 22 participants with SBMA underwent laboratory analysis and liver imaging. In the second group, 1...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729799/ https://www.ncbi.nlm.nih.gov/pubmed/29142082 http://dx.doi.org/10.1212/WNL.0000000000004748 |
_version_ | 1783286252627296256 |
---|---|
author | Guber, Robert D. Takyar, Varun Kokkinis, Angela Fox, Derrick A. Alao, Hawwa Kats, Ilona Bakar, Dara Remaley, Alan T. Hewitt, Stephen M. Kleiner, David E. Liu, Chia-Ying Hadigan, Colleen Fischbeck, Kenneth H. Rotman, Yaron Grunseich, Christopher |
author_facet | Guber, Robert D. Takyar, Varun Kokkinis, Angela Fox, Derrick A. Alao, Hawwa Kats, Ilona Bakar, Dara Remaley, Alan T. Hewitt, Stephen M. Kleiner, David E. Liu, Chia-Ying Hadigan, Colleen Fischbeck, Kenneth H. Rotman, Yaron Grunseich, Christopher |
author_sort | Guber, Robert D. |
collection | PubMed |
description | OBJECTIVE: To determine the prevalence and features of fatty liver disease in spinal and bulbar muscular atrophy (SBMA). METHODS: Two groups of participants with SBMA were evaluated. In the first group, 22 participants with SBMA underwent laboratory analysis and liver imaging. In the second group, 14 participants with SBMA were compared to 13 female carriers and 23 controls. Liver biopsies were done in 4 participants with SBMA. RESULTS: Evidence of fatty liver disease was detected by magnetic resonance spectroscopy in all participants with SBMA in the first group, with an average dome intrahepatic triacylglycerol of 27% (range 6%–66%, ref ≤5.5%). Liver dome magnetic resonance spectroscopy measurements were significantly increased in participants with SBMA in the second group relative to age- and sex-matched controls, with average disease and male control measurements of 17% and 3%, respectively. Liver biopsies were consistent with simple steatosis in 2 participants and nonalcoholic steatohepatitis in 2 others. CONCLUSIONS: We observed evidence of nonalcoholic liver disease in nearly all of the participants with SBMA evaluated. These observations expand the phenotypic spectrum of the disease and provide a potential biomarker that can be monitored in future studies. |
format | Online Article Text |
id | pubmed-5729799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-57297992017-12-19 Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy Guber, Robert D. Takyar, Varun Kokkinis, Angela Fox, Derrick A. Alao, Hawwa Kats, Ilona Bakar, Dara Remaley, Alan T. Hewitt, Stephen M. Kleiner, David E. Liu, Chia-Ying Hadigan, Colleen Fischbeck, Kenneth H. Rotman, Yaron Grunseich, Christopher Neurology Article OBJECTIVE: To determine the prevalence and features of fatty liver disease in spinal and bulbar muscular atrophy (SBMA). METHODS: Two groups of participants with SBMA were evaluated. In the first group, 22 participants with SBMA underwent laboratory analysis and liver imaging. In the second group, 14 participants with SBMA were compared to 13 female carriers and 23 controls. Liver biopsies were done in 4 participants with SBMA. RESULTS: Evidence of fatty liver disease was detected by magnetic resonance spectroscopy in all participants with SBMA in the first group, with an average dome intrahepatic triacylglycerol of 27% (range 6%–66%, ref ≤5.5%). Liver dome magnetic resonance spectroscopy measurements were significantly increased in participants with SBMA in the second group relative to age- and sex-matched controls, with average disease and male control measurements of 17% and 3%, respectively. Liver biopsies were consistent with simple steatosis in 2 participants and nonalcoholic steatohepatitis in 2 others. CONCLUSIONS: We observed evidence of nonalcoholic liver disease in nearly all of the participants with SBMA evaluated. These observations expand the phenotypic spectrum of the disease and provide a potential biomarker that can be monitored in future studies. Lippincott Williams & Wilkins 2017-12-12 /pmc/articles/PMC5729799/ /pubmed/29142082 http://dx.doi.org/10.1212/WNL.0000000000004748 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Guber, Robert D. Takyar, Varun Kokkinis, Angela Fox, Derrick A. Alao, Hawwa Kats, Ilona Bakar, Dara Remaley, Alan T. Hewitt, Stephen M. Kleiner, David E. Liu, Chia-Ying Hadigan, Colleen Fischbeck, Kenneth H. Rotman, Yaron Grunseich, Christopher Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy |
title | Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy |
title_full | Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy |
title_fullStr | Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy |
title_full_unstemmed | Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy |
title_short | Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy |
title_sort | nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729799/ https://www.ncbi.nlm.nih.gov/pubmed/29142082 http://dx.doi.org/10.1212/WNL.0000000000004748 |
work_keys_str_mv | AT guberrobertd nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT takyarvarun nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT kokkinisangela nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT foxderricka nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT alaohawwa nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT katsilona nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT bakardara nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT remaleyalant nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT hewittstephenm nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT kleinerdavide nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT liuchiaying nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT hadigancolleen nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT fischbeckkennethh nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT rotmanyaron nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy AT grunseichchristopher nonalcoholicfattyliverdiseaseinspinalandbulbarmuscularatrophy |